Pan Cancer T
Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.
Pan Cancer T
The company develops next-generation TCR-T cell therapies for solid cancers, targeting novel targets and enhancing T cell durability to overcome tumor suppression.
About
Needs Assessment
Active buying signals and potential business opportunities
Technology Requirements
Next-generation TCR-T cell therapies expertise
Advancement of adoptive T cell therapy through gene-engineering
Tools and platforms for discovery of dark antigen-specific TCRs
Service Requirements
Clinical Development, from Phase 1 through to Life Cycle Management
Expertise in effective options for patients suffering from difficult to treat tumors
Consulting on integrating retroviral vector development
Infrastructure Requirements
Cell and gene therapies manufacturing facilities
Capabilities from research to clinic
Hardware and cloud infrastructure for processing large-scale T cell manufacturing data
Talent Requirements
Experts in T cell engineering
Specialists in large-scale T cell manufacturing
Researchers with expertise in identifying novel tumor targets
Clinical development professionals with experience in immunotherapy
AI Insights
Growth Trajectory
The company is positioned for growth, indicated by their focus on expanding clinical programs, securing funding through seed extension rounds, and establishing partnerships for research and manufacturing.
Market Opportunity
The company has a strong market opportunity by focusing on untapped and unique tumor-restricted targets, offering a potential competitive advantage in the immunotherapy space.
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats